PAIN RELIEVER COMPOSITION
US20130236530A1
2013-09-12
13/417,053
2012-03-09
Abstract:
A pain reliever comprised of dextrose, aloe vera concentrate, and some or all of the following ingredients: propylene glycol, caprylic/capric tryglicerides, sodium chloride (or acetic acid), a homeopathic anti-inflamatory extract, Dimethyl Sulfone (or Methylsulfonylmethane (MSM)), cetyl myristoleate, and a pitcher plant extract. The resulting compositions are a water-based solution and two gel composition applied to the epidermis of mammals for relieving pain.
Interested in similar patents?
Get notified when new applications in this technology area are published.
Classification:
A61K9/0009 » CPC further
Medicinal preparations characterised by special physical form; Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
A61K9/0014 » CPC further
Medicinal preparations characterised by special physical form; Galenical forms characterised by the site of application Skin, i.e. galenical aspects of topical compositions
A61K9/06 » CPC further
Medicinal preparations characterised by special physical form Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
A61K9/08 » CPC further
Medicinal preparations characterised by special physical form Solutions
A61K45/06 » CPC further
Medicinal preparations containing active ingredients not provided for in groups - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K47/02 » CPC further
Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient Inorganic compounds
A61K47/10 » CPC further
Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient; Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
A61K47/14 » CPC further
Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient; Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K47/26 » CPC further
Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient; Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61K2300/00 » CPC further
Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups -
A61K9/127 IPC
Medicinal preparations characterised by special physical form; Dispersions; Emulsions Liposomes
A61K36/886 » CPC main
Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines; Magnoliophyta (angiosperms); Liliopsida (monocotyledons) Aloeaceae (Aloe family), e.g. aloe vera
B82Y5/00 IPC
Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Description
CROSS-REFERENCE TO RELATED APPLICATION
This application claims the benefit of non-provisional patent application Ser. No. 13/295,010 filed on Nov. 11, 2011.
FEDERALLY SPONSORED RESEARCH
Not Applicable
SEQUENCE LISTING OR PROGRAM
Not Applicable
STATEMENT REGARDING COPYRIGHTED MATERIAL
Portions of the disclosure of this patent document contain material that is subject to copyright protection. The copyright owner has no objection to the facsimile reproduction by anyone of the patent document or the patent disclosure as it appears in the Patent and Trademark Office file or records, but otherwise reserves all copyright rights whatsoever.
BACKGROUND
The invention relates to a pain reliever composition comprised of some or all of the following ingredients: dextrose, aloe vera concentrate, propylene glycol, caprylic/capric tryglicerides, sodium chloride (or acetic acid), a homeopathic anti-inflamatory extract, Dimethyl Sulfone (or methylsulfonylmethane (MSM)), cetyl myristoleate, and a pitcher plant extract.
Pain reliever compositions are known. For example, U.S. patent application Ser. No. 12/895,200 (US 2011/0076327 A1) by Lomax teaches herbal pain killer compositions, one of which comprises 50 mg each of the following ingredients formed into an approximately 600 mg tablet for oral administration to a mammal: Boswellia serrata, Tumeric, White Wilow, Harpagophytum Procumbens, Phellodendron Amurense, Paullinia Tomentosa, Milkberry, Mimosa Pudica, Lactuca Virosa, Naringen, 6-7 Dihydroxybergamottin, and Yerba mate.
Further, U.S. patent application Ser. No. 12/874,038 (US 2011/0117175 A1) by Rosenbaum teaches a pain reliever composition for medical procedures treatments comprising a sweet analgesic and a delivery vehicle, wherein the delivery vehicle is suitable for intra-oral delivery, and the sweet analgesic comprises sucrose, glucose, fructose, dextrose, maltodextrin, corn syrup, high fructose corn syrup, cyclamate, aspartame, sucralose, xylitol, cyclamate, stevia, brazzein, curculin, erythritol, glycyrrhizin, honey, luo han gua, mabinlin, monatin, miraculin, monellin, pentadia, thaumatin, acesulfame potassium, alitame, salt of aspartame-acesulfame, dulcin, glucin, neohyesperidin dihydrochalcone, neotame, P-4000, saccharin, or a combination thereof.
Finally, U.S. patent application Ser. No. 11/305,552 (US 2008/0102107 A1) by Lewellyn teaches a transdermal joint pain therapy composition comprising (a) from about 2.5% to about 15%, based on the total weight of said transdermal joint therapy composition, of glutamine; (b) from about 0.04% to about 0.5%, based on the total weight of said transdermal joint pain therapy composition, of hyaluronic acid; (c) from about 2.55 to about 10.0%, based on the total weight of said transdermal joint pain therapy composition, of methylsulfonylmethane; and (d) from about 70% to about 95%, based on the total weight of said transdermal joint pain therapy composition, of a transdermal delivery agent.
The objective of the present invention is to develop an alternate form of pain relief composition using different active ingredients and in different quantities that is applied to the epidermis of mammals.
SUMMARY
The inventive pain reliever composition comprises a pain relief composition applied to the epidermis of mammals in form of a water-based solution and gels comprising dextrose and aloe vera concentrate, and further comprising some or all of the following ingredients: propylene glycol, caprylic/capric tryglicerides, sodium chloride (or acetic acid), a homeopathic anti-inflamatory extract, such as Traumeel®, Dimethyl Sulfone (or Methylsulfonylmethane (MSM)), cetyl myristoleate, lipoderm base, distilled water, and a pitcher plant extract, such as Sarapin.
The lipoderm base can be substituted by any of the following; (1) lecthicin or other fat soluble granules (2) PLO (Pluronic Lecithin Organogel) (3) Urea, (4) Oleic acid, (5) Liposomes, (6) Niosomes, or (7) Nanotechnology, namely, any one of the following chosen from a group consisting of nanocrystals, liposomes, nanoparticle-protein conjugates, magnetic nanoparticles, nanogels and biodegradable nanoparticlea. There are three preferred embodiments of the invention.
The first embodiment comprises aloe vera concentrate, propylene glycol, sterile water, and sodium chloride, in amounts ranging from 0.01% to 75% of the composition, but preferably comprising at least 5% anhydrous dextrose or 1% to 50% hypertonic saline (preferably 20%), at least 10% aloe vera concentrate, and at least 10% propylene glycol.
The second embodiment comprises aloe vera concentrate, propylene glycol, caprylic/capric triglycerides, ultrasound gel, and simple-gel (Hawkins), also in amounts ranging from 0.01% to 75% of the composition, but preferably comprising at least 5% anhydrous dextrose or 1% to 50% hypertonic saline (preferably 20%), at least 10% aloe vera concentrate, at least 10% propylene glycol, and at least 10% caprylic/capric triglycerides.
The third embodiment comprises anhydrous dextrose, aloe vera concentrate, ethoxy diglycol reagent, caprylic/capric triglycerides, lipoderm base, and cetyl myristoleat, in amounts ranging from 0.01% to 75%, but preferably comprising at least 20% anhydrous dextrose, at least 10% aloe vera concentrate, at least 10% caprylic/capric triglycerides, and at least 10% caprylic/capric triglycerides. Preferably, the third embodiment should further comprise at least 10% dimethyl sulfone or Methylsulfonylmethane (MSM), at least 10% pitcher plant extract, distilled water, and a homeopathic anti-inflammatory extract.
DETAILED DESCRIPTION
The inventive pain reliever comprises anhydrous dextrose and aloe vera concentrate, and some or all of the following ingredients: propylene glycol, caprylic/capric tryglicerides, sodium chloride (or acetic acid), a homeopathic anti-inflamatory extract, such as Traumeel®, Dimethyl Sulfone (or Methylsulfonylmethane (MSM)), cetyl myristoleate, lipoderm base, distilled water, and a pitcher plant extract, such as Sarapin. Each of the below-described embodiments are described in relation to a 100 gram composition.
In all embodiments, the Lipoderm base may be substituted by any of the following:
-
- (1) lecthicin or other fat soluble granules in the range of 0.001 to 75% (w/w) of the composition, preferably 5%;
- (2) PLO (Pluronic Lecithin Organogel) in the range of 0.001 to 75% of the composition in gel form, preferably 30%;
- (3) Urea in the range of 1-50% of the composition, preferably 10%;
- (4) Oleic acid in the range of 0.001 to 70% of the composition, preferably 5%;
- (5) Liposomes in the range of 0.01% to 75% of the composition;
- (6) Niosomes in the range of 0.01% to 75% of the composition; or
- (7) Nanotechnology in the range of 0.01 to 75%, namely, any one of the following chosen from a group consisting of nanocrystals, liposomes, nanoparticle-protein conjugates, magnetic nanoparticles, nanogels and biodegradable nanoparticles.
The first embodiment of the invention is a water-based solution to be applied through iontophoresis. This first embodiment comprises the following ingredients:
-
- 2-50 grams of anhydrous dextrose,
- 0.5-10 grams of aloe vera concentrate (freeze dried 40× powder),
- 1-20 ml of propylene glycol,
- 10-100 ml of sterile water, and
- 1-20 grams of sodium chloride (granular) (or acetic acid).
While the above measurements are ideal, the active ingredients can vary in range from 0.01% to 75% of the total volume of the solution. Among the active ingredients in the first embodiment are anhydrous dextrose, aloe vera concentrate, and propylene glycol.
The second embodiment of the invention is a gel which can be applied directly to the epidermis using an ultra sound machine, and can be absorbed faster than the first embodiment. The second embodiment comprises the following ingredients:
-
- 2-50 grams of anhydrous dextrose,
- 0.5-10 grams of aloe vera concentrate (freeze dried 40× powder),
- 1-20 ml of propylene glycol,
- 0.5-5 ml of caprylic/capric triglycerides
- 10-100 grams of ultrasound gel
- 0.25-5 ml of simple-gel (Hawkins) gel.
While the above measurements are ideal, the active ingredients can vary in range from 0.01% to 75% of the total volume of the solution. Among the active ingredients in the second embodiment are anhydrous dextrose, aloe vera concentrate, propylene glycol, and caprylic/capric triglycerides.
The third embodiment of the invention is also a gel which can be applied directly to the epidermis without the use an ultra sound machine or iontophoresis, and can be absorbed faster than the first and second embodiment. The third embodiment comprises the following ingredients:
-
- 2-50 grams of anhydrous dextrose,
- 0.5-10 grams of aloe vera concentrate (freeze dried 40× powder),
- 0.5-5 ml of caprylic/capric triglycerides
- 1-10 ml of ethoxy diglycol reagent
- 5-10 grams of a lipoderm base
- 0.1-5 grams of cetyl myristoleate
The following optional ingredients may be added to the third embodiment:
-
- 0.5-5 grams of dimethyl sulfone (or MSM)
- 0.5-5 ml of pitcher plant extract (1:2 solution), such as Sarapin®.
- 1-20 ml of distilled water, and
- 0.5-20 tablets of a homeopathic anti-inflamatory extract, such as Traumeel®
While the above measurements are ideal, the active ingredients can vary in range from 0.01% to 75% of the total volume of the solution. Among the active ingredients in the third embodiment are anhydrous dextrose, aloe vera concentrate, caprylic/capric triglycerides, ethoxy diglycol reagent, lipoderm base, and cetyl myristoleate.
Whenever the following ingredients are used in any of the above three embodiments, the recommended percentage of the solution or gel should be as follows:
-
- dextrose at least 5% or 1-50%, preferably 20%, of hypertonic saline
- aloe vera concentrate 10%
- propylene glycol 10%
- caprylic/capric triglycerides 10%
- sodium chloride (or acetic acid) 10%
- homeopathic anti-inflamatory extract, such as Traumeel® 10%
- dimethyl sulfone (or MSM) 10%
- cetyl myristoleat 10%
- pitcher plant extract, such as Sarapin® 10%.
Although preferred embodiments of the present invention have been shown and described, various modifications and substitutions may be made thereto without departing from the spirit and scope of the invention. Accordingly, it is to be understood that the present invention has been described by way of illustration and not limitation.
Claims
What is claimed is:1. A water-based pain reliever composition applied to the epidermis of mammals comprised of
anhydrous dextrose or hypertonic saline;
aloe vera concentrate;
propylene glycol;
sterile water; and
any one of the following: sodium chloride, acetic acid or hypertonic saline;
all in amounts ranging from 0.01% to 75% of the composition.
2. The pain reliever composition of claim 1, wherein
at least 5% is anhydrous dextrose or 1% to 50% hypertonic saline;
10% is aloe vera concentrate; and
at least 10% is propylene glycol.
3. The pain reliever composition of claim 1, wherein, out of a 100 gram composition, the pain reliever composition comprises:
2-50 grams of anhydrous dextrose or 1-50% hypertonic saline;
0.5-10 grams of aloe vera concentrate constitutes 0.5-10 grams;
1-20 ml of propylene glycol;
10-100 ml of sterile water; and
1-20 grams of sodium chloride or acetic acid.
4. A gel-based pain reliever composition applied to the epidermis of mammals comprised of anhydrous dextrose or hypertonic saline, aloe vera concentrate, propylene glycol, caprylic/capric triglycerides, ultrasound gel, and simple-gel (Hawkins), in amounts ranging from 0.01% to 75% of the composition.
5. The pain reliever composition of claim 4, wherein
at least 5% is anhydrous dextrose or 1-50% is hypertonic saline;
at least 10% is aloe vera concentrate;
at least 10% is propylene glycol, and
at least 10% is caprylic/capric triglycerides.
6. The pain reliever composition of claim 4, wherein, out of a 100 gram composition,
2-50 grams is anhydrous dextrose;
5-10 grams is aloe vera concentrate;
1-20 ml is propylene glycol;
0.5-5 ml is caprylic/capric triglycerides;
10-100 grams is ultrasound gel, and
0.25-5 ml is simple-gel (Hawkins) gel.
7. A gel-based pain reliever composition applied to the epidermis of mammals comprised of anhydrous dextrose, aloe vera concentrate, ethoxy diglycol reagent, caprylic/capric triglycerides, lipoderm base, and cetyl myristoleat, in amounts ranging from 0.01% to 75% of the composition; the lipoderm base being substitutable by any of the following:
lecthicin or other fat soluble granules in the range of 0.001 to 75% (w/w) of the composition;
PLO (Pluronic Lecithin Organogel) in the range of 0.001 to 75% of the composition in gel form;
Urea in the range of 1-50% of the composition;
Oleic acid in the range of 0.001 to 70% of the composition;
Liposomes in the range of 0.01% to 75% of the composition;
Niosomes in the range of 0.01% to 75% of the composition; or
Nanotechnology in the range of 0.01 to 75% chosen from a group consisting of nanocrystals, liposomes, nanoparticle-protein conjugates, magnetic nanoparticles, nanogels and biodegradable nanoparticles.
8. The pain reliever composition of claim 7, wherein
at least 5% is anhydrous dextrose or 1-50% is hypertonic saline;
at least 10% is aloe vera concentrate; and
at least 10% is caprylic/capric triglycerides.
9. The pain reliever composition of claim 7, wherein, out of a 100 gram composition,
2-50 grams is anhydrous dextrose;
5-10 grams is aloe vera concentrate constitutes;
0.5-5 ml is caprylic/capric triglycerides;
1-10 ml is ethoxy diglycol reagent;
5-10 grams lipoderm base; and
0.1-5 grams cetyl myristoleat;
Where 5-10 grams lipoderm base can be substituted by any of the following:
5% lecthicin or other fat soluble granules;
30% PLO (Pluronic Lecithin Organogel) in gel form;
10% Urea;
% Oleic acid;
0.01% to 75% Liposomes;
0.01% to 75% Niosomes; or
0.01% to 75% Nanotechnology chosen from a group consisting of nanocrystals, liposomes, nanoparticle-protein conjugates, magnetic nanoparticles, nanogels and biodegradable nanoparticles.
10. The pain reliever composition of claim 7, further comprising at least 10% dimethyl sulfone or Methylsulfonylmethane (MSM), at least 10% pitcher plant extract, distilled water, and a homeopathic anti-inflammatory extract.
11. The pain reliever composition of claim 9, further comprising
0.5-5 grams of dimethyl sulfone Methylsulfonylmethane (MSM);
0.5-5 ml of pitcher plant extract (1:2 solution);
1-20 ml of distilled water; and
0.5-20 tablets of a homeopathic anti-inflammatory extract.